CD276 and colorectal carcinoma: Given our results that B7-H3 played important roles in low-dose DOX-induced senescence of CRC cells in vitro and in vivo, we speculated that combination B7-H3 blockade therapy and TIS therapy based on low-dose DOX would become a promising strategy for CRC patients.